The phosphodiesterase inhibitor isobutylmethylxanthine attenuates behavioral sensitization to cocaine

Behavioural Pharmacology

Volumn 23, Issue 3, 2012, Pages 310-314

  Schroeder, Joseph A ^a   Ruta, Jeffrey D ^a   Gordon, Jessica S ^a   Rodrigues, Andrea S ^a   Foote, Christopher C ^a  

^a The Holleran Center for Community Action and Public Policy   (United States)

Author keywords

Adenosine; cAMP; Cocaine behavioral sensitization; Isobutylmethylxanthine; Phosphodiesterase; Rat

Indexed keywords

ADENOSINE; COCAINE; CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BEHAVIORAL SENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; NUCLEOTIDE METABOLISM; RAT; SENSITIZATION;

1-METHYL-3-ISOBUTYLXANTHINE; ADENOSINE; ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; COCAINE; CYCLIC AMP; MALE; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84860753241     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283536d04     Document Type: Article

References (39)

1. Beavo JA, Reifsnyder DH (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155.
2. Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV (1970). Effects of xanthine derivatives on lipolysis and on adenosine 30,50-monophosphate phosphodiesterase activity. Mol Pharmacol 6:597-603.
3. Bonci A,Williams JT (1996). A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 16:631-639.
4. Chao J, Nestler EJ (2004). Molecular neurobiology of drug addiction. Annu Rev Med 55:113-132.
5. Chung KM, Choi SS, Choi MR, Suh HW (2003). Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on immobilization stress-induced antinociception in the mouse. Eur Neuropsychopharmacol 13:281-288.
6. Coffin VL, Spealman RD (1989). Psychomotor-stimulant effects of 3-isobutyl-1-methylxanthine: comparison with caffeine and 7-(2-chloroethyl) theophylline. Eur J Pharmacol 170:35-40.
7. Cornish JL, Kalivas PW (2001). Repeated cocaine administration into the rat ventral tegmental area produces behavioral sensitization to a systemic cocaine challenge. Behav Brain Res 126:205-209.
8. Davis CW (1984). Assessment of selective inhibition of rat cerebral cortical calcium-independent and calciumdependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochem Biophys Acta 797:354-362.
9. Downs AW, Eddy NB (1932). The effect of repeated doses of cocaine on the rat. J Pharmacol Exp Ther 46:199-202.
10. Dunwiddie TV, Diao L, Proctor WR (1997). Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracelllular space in rat hippocampus. J Neurosci 17:7673-7682.
11. Fiorillo CD, Williams JT (2000). Selective inhibition by adenosine of mGluR IPSPs in dopamine neurons after cocaine treatment. J Neurophysiol 83:1307-1314.
12. Galloway MP, Roth RH (1983). Neuropharmacology of 3- isobutylmethylxanthine: effects on central noradrenergic systems in vivo. JPET 227:1-8.
13. Gardner C, Robas N, Cawkill D, Fidock M (2000). Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272:186-192.
14. Hack SP, Christie MJ (2003). Adaptations in adenosine signaling in drug dependence: therapeutic implications. Crit Rev Neurobiol 15:235-274.
15. Hutson PH, Suman-Chauhan N (1990). Activation of postsynaptic striatal dopamine receptors, monitored by efflux of cAMP in vivo. Neuropharmacology 29:1011-1016.
16. Jackson EK, Mi Z, Dubey RK (2007). The extracellular cAMP-adenosine pathway significantly contributes to the in vivo production of adenosine. J Pharmacol Exp Ther 320:117-123.
17. Jimé nez-Rivera CA, Feliu-Mojer M, Vázquez-Torres R (2006). Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann NY Acad Sci 1074:390-402.
18. Kalivas PW, Pierce RC, Cornish J, Sorg BA (1998). A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 12:49-53.
19. Kaulen P, Brü ning G, Schneider HH, Sarter M, Baumgarten HG (1989). Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229-245.
20. Mi Z, Herzer WA, Zhang Y, Jackson EK (1994). 3-Isobutyl-1-methylxanthine decreases renal cortical interstitial levels of adenosine and inosine. Life Sci 54:277-282.
21. Michaelis ML, Johe KK, Moghadam B, Adams RN (1988). Studies on the ionic mechanism for the neuromodulatory actions of adenosine in the brain. Brain Res 473:249-260.
22. Morton GJ, Blevins JE, Kim F, Matsen M, Figlewicz DP (2009). The action of leptin in the ventral tegmental area to decrease food intake is dependent on Jak-2 signaling. Am J Physiol Endocrinol Metab 297:E202-E210.
23. Nakata H (1989). Affinity chromatography of A1 adenosine receptors of rat brain membranes. Mol Pharmacol 35:780-786.
24. Nestler EJ, Aghajanian GK (1997). Molecular and cellular basis of addiction. Science 278:58-63.
25. Paxinos G, Watson C (1998). The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press.
26. Post R, Rose H (1976). Increasing effects of receptive cocaine administration in the rat. Nature 260:731-732.
27. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentivesensitization theory of addiction. Brain Res Rev 18:247-291.
28. Sanna F, Succu S, Boi A, Melis MR, Argiolas A (2009). Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. J Sex Med 10:2680-2689.
29. Schenk S, Partridge B (1999). Cocaine-seeking produced by experimenteradministered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl) 147:285-290.
30. Schenk S, Worley CM, McNamara C, Valadez A (1996). Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology (Berl) 126:17-23.
31. Self DW, Nestler EJ (1995). Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463-495.
32. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW (1981). Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci USA 78:3260-3264.
33. Suh HW, Sim YB, Choi YS, Song DK, Kim YH (1995). Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin. Gen Pharmacol 26:1597-1602.
34. Suh HW, Song DK, Kwon SH, Kim KW, Min BH, Kim YH (1997). Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on cold water swimming stress-induced antinociception in the mouse. Gen Pharmacol 28:607-610.
35. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ (1991). A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548:100-110.
36. Unterwald EM, Fillmore J, Kreek MJ (1996). Chronic repeated cocaine administration increase dopamine D1 receptor-mediated signal transduction. Eur J Pharm 318:31-35.
37. Weishaar RE, Cain MH, Bristol JA (1985). A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and its potential for drug selectivity. J Med Chem 28:537-545.
38. Zhang Y, Loonam TM, Noailles PA, Angulo JA (2001). Comparison of cocaineand methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann NY Acad Sci 937:93-120.
39. Zimmermann H (1996). Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog Neurobiol 49: 589-618.